BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26:2131-2138. [PMID: 18299612 DOI: 10.1200/jco.2006.10.4182] [Cited by in Crossref: 277] [Cited by in F6Publishing: 95] [Article Influence: 19.8] [Reference Citation Analysis]
Number Citing Articles
1 O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009;15:4806-4814. [PMID: 19622575 DOI: 10.1158/1078-0432.ccr-09-0344] [Cited by in Crossref: 134] [Cited by in F6Publishing: 87] [Article Influence: 10.3] [Reference Citation Analysis]
2 Yang C, Peng S, Sun Y, Miao H, Lyu M, Ma S, Luo Y, Xiong R, Xie C, Quan H. Development of a hypoxic nanocomposite containing high-Z element as 5-fluorouracil carrier activated self-amplified chemoradiotherapy co-enhancement. R Soc Open Sci 2019;6:181790. [PMID: 31312471 DOI: 10.1098/rsos.181790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251-261. [PMID: 22943016 DOI: 10.3978/j.issn.2078-6891.2012.021] [Cited by in F6Publishing: 160] [Reference Citation Analysis]
4 Iachetta F, Bonelli C, Romagnani A, Zamponi R, Tofani L, Farnetti E, Nicoli D, Damato A, Banzi M, Casali B, Pinto C. The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. Br J Cancer 2019;120:834-9. [PMID: 30858516 DOI: 10.1038/s41416-019-0423-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Khushman M, Patel GK, Hosein PJ, Laurini JA, Cameron D, Clarkson DR, Butler TW, Norden CW, Baliem W, Jones V, Bhadkamkar S, Nelson C, Lee F, Singh AP, Taylor WR. Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. J Gastrointest Oncol 2018;9:416-24. [PMID: 29998006 DOI: 10.21037/jgo.2018.02.03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Kamio H, Uchiyama T, Kanno H, Onoe Y, Saito K, Kameoka S, Kamio T, Okamoto T. Association between SLCO1B1 rs4149056 and tegafur-uracil-induced hepatic dysfunction in breast cancer. Pharmacogenomics 2019;20:353-65. [PMID: 30734632 DOI: 10.2217/pgs-2018-0100] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55. [PMID: 19147868 DOI: 10.3322/caac.20002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 6.7] [Reference Citation Analysis]
8 Nazarian A, Kulminski AM. Genome-Wide Analysis of Sex Disparities in the Genetic Architecture of Lung and Colorectal Cancers. Genes (Basel) 2021;12:686. [PMID: 34062886 DOI: 10.3390/genes12050686] [Reference Citation Analysis]
9 Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013;108:2505-15. [PMID: 23736036 DOI: 10.1038/bjc.2013.262] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 10.9] [Reference Citation Analysis]
10 Gusella M, Frigo AC, Bolzonella C, Marinelli R, Barile C, Bononi A, Crepaldi G, Menon D, Stievano L, Toso S. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer. 2009;100:1549-1557. [PMID: 19384296 DOI: 10.1038/sj.bjc.6605052] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 5.5] [Reference Citation Analysis]
11 Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist. 2011;16:820-834. [PMID: 21632461 DOI: 10.1634/theoncologist.2010-0259] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
12 Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M, Costa VL, Rodrigues A, Dias PC, Veiga I, Machado M, Teixeira MR, Henrique R, Jerónimo C. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 2010;10:470. [PMID: 20809970 DOI: 10.1186/1471-2407-10-470] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
13 Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103:210-216. [PMID: 29152729 DOI: 10.1002/cpt.911] [Cited by in Crossref: 177] [Cited by in F6Publishing: 153] [Article Influence: 35.4] [Reference Citation Analysis]
14 Gu J, Wang YS, Wang M, Li YM, Wang YJ. Treatment of gastric cardia cancer with capecitabine and oxaliplatin: an analysis of 46 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(30): 3443-3447 [DOI: 10.11569/wcjd.v16.i30.3443] [Reference Citation Analysis]
15 Ghosh S, Winter JM, Patel K, Kern SE. Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency. Cancer Biol Ther 2011;12:750-5. [PMID: 21811101 DOI: 10.4161/cbt.12.8.16867] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
16 Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, Lordick F, Meindl A. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008;3:e4003. [PMID: 19104657 DOI: 10.1371/journal.pone.0004003] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
17 Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clin Cancer Res 2017;23:7543-9. [PMID: 28972045 DOI: 10.1158/1078-0432.CCR-16-3142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
18 Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. J Natl Cancer Inst 2021;113:400-7. [PMID: 32835356 DOI: 10.1093/jnci/djaa124] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
19 Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer. 2009;101:998-1004. [PMID: 19672255 DOI: 10.1038/sj.bjc.6605239] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
20 Leung HW, Chan AL. Association and prediction of severe 5-fluorouracil toxicity with dihydropyrimidine dehydrogenase gene polymorphisms: A meta-analysis. Biomed Rep 2015;3:879-83. [PMID: 26623034 DOI: 10.3892/br.2015.513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21:237-242. [PMID: 20601926 DOI: 10.1097/fpc.0b013e32833c6107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
22 Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, Borro M. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharmacogenomics J 2016;16:320-5. [PMID: 26216193 DOI: 10.1038/tpj.2015.56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
23 Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin Pharmacol Ther 2009;86:109-13. [PMID: 19369936 DOI: 10.1038/clpt.2009.39] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
24 Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB. Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity. Clin Pharmacol Ther 2017;102:662-70. [PMID: 28295243 DOI: 10.1002/cpt.685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
25 Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther 2014;95:269-80. [PMID: 24136381 DOI: 10.1038/clpt.2013.214] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
26 Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545-2554. [PMID: 24648345 DOI: 10.1158/0008-5472.can-13-2482] [Cited by in Crossref: 94] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]
27 Alexandru M, Rodica A, Dragos-Eugen G, Mihai-Teodor G. Assessing the Spleen as an Organ at Risk in Radiation Therapy and Its Relationship With Radiation-Induced Lymphopenia: A Retrospective Study and Literature Review. Adv Radiat Oncol 2021;6:100761. [PMID: 34934857 DOI: 10.1016/j.adro.2021.100761] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Saijo N. The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Med J 2013;54:1-14. [PMID: 23225792 DOI: 10.3349/ymj.2013.54.1.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
29 Conti V, De Bellis E, Manzo V, Sabbatino F, Iannello F, Dal Piaz F, Izzo V, Charlier B, Stefanelli B, Torsiello M, Iannaccone T, Coglianese A, Colucci F, Pepe S, Filippelli A. A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature. J Pers Med 2020;10:E113. [PMID: 32899374 DOI: 10.3390/jpm10030113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
30 Mezzalira S, Toffoli G. The effects of sex on pharmacogenetically guided drug treatment. Pharmacogenomics 2021;22:959-62. [PMID: 34545749 DOI: 10.2217/pgs-2021-0088] [Reference Citation Analysis]
31 Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther 2013;94:158-66. [PMID: 23588312 DOI: 10.1038/clpt.2013.69] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
32 Zou Y, Liu S, Wu J, Sun Z. Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature. World J Surg Oncol 2021;19:332. [PMID: 34809643 DOI: 10.1186/s12957-021-02443-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Palmirotta R, Lovero D, Delacour H, Le Roy A, Cremades S, Silvestris F. Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. Front Oncol 2019;9:139. [PMID: 30915274 DOI: 10.3389/fonc.2019.00139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, Turner R, Epurescu D, Barrett A, Willis G. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One 2013;8:e78053. [PMID: 24167597 DOI: 10.1371/journal.pone.0078053] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
35 Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031-1039. [PMID: 24590654 DOI: 10.1200/jco.2013.51.1857] [Cited by in Crossref: 145] [Cited by in F6Publishing: 72] [Article Influence: 18.1] [Reference Citation Analysis]
36 Puga AM, Lopez-Oliva S, Trives C, Partearroyo T, Varela-Moreiras G. Effects of Drugs and Excipients on Hydration Status. Nutrients 2019;11:E669. [PMID: 30897748 DOI: 10.3390/nu11030669] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, Parisi G, Calvetti L, Sonis ST. New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Front Pharmacol 2017;8:354. [PMID: 28642709 DOI: 10.3389/fphar.2017.00354] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 14.6] [Reference Citation Analysis]
38 Wang Y, Jia X, Qiao Y, Xu L, Zhang X, Li Q, Wang P, Sun W, Wu J. Association Between Nonsyndromic Cleft Lip and Palate and 2 Polymorphic Loci: A Meta-Analysis. Cleft Palate Craniofac J 2021;58:763-72. [PMID: 33025822 DOI: 10.1177/1055665620962686] [Reference Citation Analysis]
39 Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013;21:3233-41. [PMID: 23842598 DOI: 10.1007/s00520-013-1900-x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 8.6] [Reference Citation Analysis]
40 Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. Br J Cancer 2020;122:812-22. [PMID: 31942030 DOI: 10.1038/s41416-019-0707-z] [Reference Citation Analysis]
41 Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R. DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget. 2018;9:7859-7866. [PMID: 29487697 DOI: 10.18632/oncotarget.23559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
42 Arshad U, Ploylearmsaeng SA, Karlsson MO, Doroshyenko O, Langer D, Schömig E, Kunze S, Güner SA, Skripnichenko R, Ullah S, Jaehde U, Fuhr U, Jetter A, Taubert M. Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. Cancer Chemother Pharmacol 2020;85:711-22. [PMID: 32152679 DOI: 10.1007/s00280-019-04028-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E, Pietrantonio F. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. Int J Mol Sci 2015;16:8884-95. [PMID: 25906475 DOI: 10.3390/ijms16048884] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
44 Lin S, Yue J, Guan X, Yuan P, Wang J, Luo Y, Fan Y, Cai R, Li Q, Chen S, Zhang P, Li Q, Ma F, Xu B. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer Commun (Lond) 2019;39:57. [PMID: 31601265 DOI: 10.1186/s40880-019-0399-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
45 Schaerer D, Froehlich TK, Hamzic S, Offer SM, Diasio RB, Joerger M, Amstutz U, Largiadèr CR. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. J Pers Med 2020;10:E181. [PMID: 33086767 DOI: 10.3390/jpm10040181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Paré L, Paez D, Salazar J, Del Rio E, Tizzano E, Marcuello E, Baiget M. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Br J Clin Pharmacol 2010;70:268-72. [PMID: 20653680 DOI: 10.1111/j.1365-2125.2010.03683.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
47 Lindner AU, Resler AJ, Carberry S, Oficjalska K, Bacon O, Lee CS, Choudhry A, Burke JP, Sheahan K, Cremona M, Hennessy BT, McNamara D, Doherty G, Ryan EJ, Prehn JHM. Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. J Mol Med (Berl) 2020;98:149-59. [PMID: 31848663 DOI: 10.1007/s00109-019-01864-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Tsutsui M, Yamamoto S, Yoshikawa Y, Nakanishi R, Takano K, Osumi K, Akatsu T, Yoneyama K, Nakagawa M, Kanai T. Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report. Int Cancer Conf J 2018;7:125-9. [PMID: 31149530 DOI: 10.1007/s13691-018-0334-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB. Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther 2017;101:382-90. [PMID: 27727460 DOI: 10.1002/cpt.531] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
50 Peterson DE, Bensadoun RJ, Roila F;  ESMO Guidelines Working Group. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi78-vi84. [PMID: 21908510 DOI: 10.1093/annonc/mdr391] [Cited by in Crossref: 126] [Cited by in F6Publishing: 108] [Article Influence: 11.5] [Reference Citation Analysis]
51 Soo RA, Syn N, Lee SC, Wang L, Lim XY, Loh M, Tan SH, Zee YK, Wong AL, Chuah B, Chan D, Lim SE, Goh BC, Soong R, Yong WP. Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours. Sci Rep 2016;6:27826. [PMID: 27296624 DOI: 10.1038/srep27826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
52 Amstutz U, Farese S, Aebi S, Largiadèr CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res. 2008;27:54. [PMID: 18937829 DOI: 10.1186/1756-9966-27-54] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
53 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20(29): 9775-9827 [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
54 Palmirotta R, Carella C, Silvestris E, Cives M, Stucci SL, Tucci M, Lovero D, Silvestris F. SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget 2018;9:25355-82. [PMID: 29861877 DOI: 10.18632/oncotarget.25256] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
55 Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol. 2010;69:58-66. [PMID: 20078613 DOI: 10.1111/j.1365-2125.2009.03556.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
56 Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. Oncologist 2021. [PMID: 34506675 DOI: 10.1002/onco.13967] [Reference Citation Analysis]
57 Kwon Y. Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. Onco Targets Ther 2016;9:2007-16. [PMID: 27103826 DOI: 10.2147/OTT.S96899] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
58 Božina N, Bilić I, Ganoci L, Šimičević L, Pleština S, Lešnjaković L, Trkulja V. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol 2021. [PMID: 34780066 DOI: 10.1111/bcp.15144] [Reference Citation Analysis]
59 Alessandrini M, Chaudhry M, Dodgen TM, Pepper MS. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade. OMICS 2016;20:593-603. [PMID: 27643672 DOI: 10.1089/omi.2016.0122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
60 Yamada Y, Muro K, Takahashi K, Baba H, Komatsu Y, Satoh T, Goto M, Mishima H, Watanabe M, Sakata Y, Morita S, Shimada Y, Takenaka N, Hirooka T, Sugihara K. Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. Glob Health Med 2020;2:240-6. [PMID: 33330814 DOI: 10.35772/ghm.2020.01050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
62 Zhang S, Tan IB, Sapari NS, Grabsch HI, Okines A, Smyth EC, Aoyama T, Hewitt LC, Inam I, Bottomley D, Nankivell M, Stenning SP, Cunningham D, Wotherspoon A, Tsuburaya A, Yoshikawa T, Soong R, Tan P. Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2015;17:242-50. [PMID: 25746798 DOI: 10.1016/j.jmoldx.2014.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
63 Bowen JM, White I, Smith L, Tsykin A, Kristaly K, Thompson SK, Karapetis CS, Tan H, Game PA, Irvine T. Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. Support Care Cancer. 2015;23:3165-3172. [PMID: 25814442 DOI: 10.1007/s00520-015-2696-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
64 Peterson DE, Lalla RV. Oral mucositis: the new paradigms. Curr Opin Oncol 2010;22:318-22. [PMID: 20485169 DOI: 10.1097/CCO.0b013e32833a9fab] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
65 Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin Proc 2014;89:131-6. [PMID: 24388031 DOI: 10.1016/j.mayocp.2013.09.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
66 Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 2014;42:124-39. [PMID: 24178577 DOI: 10.1177/0192623313505155] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
67 Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV; Mucositis Study Group of Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013;21:2075-83. [PMID: 23604521 DOI: 10.1007/s00520-013-1810-y] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
68 Crea F, Duhagon MA, Farrar WL, Danesi R. Pharmacogenomics and cancer stem cells: a changing landscape? Trends Pharmacol Sci 2011;32:487-94. [PMID: 21529973 DOI: 10.1016/j.tips.2011.03.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
69 Ludovini V, Antognelli C, Rulli A, Foglietta J, Pistola L, Eliana R, Floriani I, Nocentini G, Tofanetti FR, Piattoni S, Minenza E, Talesa VN, Sidoni A, Tonato M, Crinò L, Gori S. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy. BMC Cancer 2017;17:502. [PMID: 28747156 DOI: 10.1186/s12885-017-3483-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
70 Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, Gunn GB, Chambers MS, Hanna EY, Yeung SJ, Shete S. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One 2017;12:e0180396. [PMID: 28678827 DOI: 10.1371/journal.pone.0180396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
71 Crona D, Innocenti F. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med 2012;6:349-62. [PMID: 22731909 DOI: 10.2217/bmm.12.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
72 Vivaldi C, Crucitta S, Catanese S, Cucchiara F, Arrigoni E, Pecora I, Rofi E, Fornaro L, Salani F, Massa V, Vasile E, Morganti R, Danesi R, Del Re M. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Pharmacogenomics J 2021;21:233-42. [PMID: 33462346 DOI: 10.1038/s41397-020-00203-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Pesenti C, Gusella M, Sirchia SM, Miozzo M. Germline oncopharmacogenetics, a promising field in cancer therapy. Cell Oncol (Dordr) 2015;38:65-89. [PMID: 25573079 DOI: 10.1007/s13402-014-0214-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
74 Tao G, Huang J, Moorthy B, Wang C, Hu M, Gao S, Ghose R. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol 2020;16:1109-24. [PMID: 32841068 DOI: 10.1080/17425255.2020.1815705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget 2016;7:20612-20. [PMID: 26967565 DOI: 10.18632/oncotarget.7991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
76 Etienne-Grimaldi MC, Bennouna J, Formento JL, Douillard JY, Francoual M, Hennebelle I, Chatelut E, Francois E, Faroux R, El Hannani C. Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol. 2012;73:776-785. [PMID: 22486600 DOI: 10.1111/j.1365-2125.2011.04141.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
77 Jolivet C, Nassabein R, Soulières D, Weng X, Amireault C, Ayoub JP, Beauregard P, Blais N, Carrier C, Cloutier AS, Desnoyers A, Lemay AS, Lemay F, Loungnarath R, Jolivet J, Letendre F, Tehfé M, Vadnais C, Viens D, Aubin F. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience. Oncologist 2021;26:e597-602. [PMID: 33274825 DOI: 10.1002/onco.13626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Wigle TJ, Tsvetkova EV, Welch SA, Kim RB. DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics. 2019;11. [PMID: 31052357 DOI: 10.3390/pharmaceutics11050199] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
79 Li Q, Liu Y, Zhang HM, Huang YP, Wang TY, Li DS, Sun HZ. Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis. Gastroenterol Res Pract 2014;2014:827989. [PMID: 25614737 DOI: 10.1155/2014/827989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
80 Wang J, Wang X, Zhao M, Choo SP, Ong SJ, Ong SY, Chong SS, Teo YY, Lee CG. Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. PLoS One 2014;9:e111694. [PMID: 25372392 DOI: 10.1371/journal.pone.0111694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
81 Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013;14:315-324. [PMID: 23394393 DOI: 10.2217/pgs.12.213] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
82 Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016;26:133-7. [PMID: 26658227 DOI: 10.1097/FPC.0000000000000197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
83 Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640-645. [PMID: 23988873 DOI: 10.1038/clpt.2013.172] [Cited by in Crossref: 218] [Cited by in F6Publishing: 195] [Article Influence: 24.2] [Reference Citation Analysis]
84 Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P. Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. Oncotarget 2017;8:14050-7. [PMID: 27738344 DOI: 10.18632/oncotarget.12571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
85 Moen EL, Godley LA, Zhang W, Dolan ME. Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med 2012;4:90. [PMID: 23199206 DOI: 10.1186/gm391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
86 Hiratsuka M, Yamashita H, Akai F, Hosono H, Hishinuma E, Hirasawa N, Mori T. Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity. PLoS One 2015;10:e0124818. [PMID: 25915935 DOI: 10.1371/journal.pone.0124818] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
87 Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, Johnstone E, Wang H, Love S, Scudder C, Julier P, Fernández-Rozadilla C, Ruiz-Ponte C, Carracedo A, Castellvi-Bel S, Castells A, Gonzalez-Neira A, Taylor J, Kerr R, Kerr D, Tomlinson I. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 2015;64:111-20. [PMID: 24647007 DOI: 10.1136/gutjnl-2013-306571] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
88 van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D, Hennekam RC, Mannens MM, Kiechle M, Etienne-Grimaldi MC. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010;128:529-538. [PMID: 20803296 DOI: 10.1007/s00439-010-0879-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 6.5] [Reference Citation Analysis]
89 Cordova-Delgado M, Bravo ML, Cumsille E, Hill CN, Muñoz-Medel M, Pinto MP, Retamal IN, Lavanderos MA, Miquel JF, Rodriguez-Fernandez M, Liao Y, Li Z, Corvalán AH, Armisén R, Garrido M, Quiñones LA, Owen GI. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer. BMC Cancer 2021;21:1030. [PMID: 34525956 DOI: 10.1186/s12885-021-08745-0] [Reference Citation Analysis]
90 Soh TI, Yong WP, Innocenti F. Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clin Chem Lab Med 2011;49:1621-32. [PMID: 21950596 DOI: 10.1515/CCLM.2011.715] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
91 Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123:345-356. [PMID: 27622829 DOI: 10.1002/cncr.30321] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
92 Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 2013;73:1958-68. [PMID: 23328581 DOI: 10.1158/0008-5472.CAN-12-3858] [Cited by in Crossref: 67] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
93 Yamada Y, Koizumi W, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Hyodo I. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Cancer Sci 2019;110:2875-83. [PMID: 31254422 DOI: 10.1111/cas.14117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
94 Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-29. [PMID: 20921207 DOI: 10.1136/gut.2009.206250] [Cited by in Crossref: 210] [Cited by in F6Publishing: 200] [Article Influence: 17.5] [Reference Citation Analysis]
95 Pilgrim CH, Brettingham-Moore K, Pham A, Murray W, Link E, Smith M, Usatoff V, Evans PM, Banting S, Thomson BN, Michael M, Phillips WA. mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. HPB (Oxford) 2011;13:811-6. [PMID: 21999595 DOI: 10.1111/j.1477-2574.2011.00365.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
96 Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel) 2019;11:E857. [PMID: 31226812 DOI: 10.3390/cancers11060857] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
97 Guerrero S, López-Cortés A, Indacochea A, García-Cárdenas JM, Zambrano AK, Cabrera-Andrade A, Guevara-Ramírez P, González DA, Leone PE, Paz-Y-Miño C. Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies. Sci Rep 2018;8:13978. [PMID: 30228363 DOI: 10.1038/s41598-018-32264-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
98 Brečević L, Rinčić M, Krsnik Ž, Sedmak G, Hamid AB, Kosyakova N, Galić I, Liehr T, Borovečki F. Association of new deletion/duplication region at chromosome 1p21 with intellectual disability, severe speech deficit and autism spectrum disorder-like behavior: an all-in approach to solving the DPYD enigma. Transl Neurosci 2015;6:59-86. [PMID: 28123791 DOI: 10.1515/tnsci-2015-0007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
99 Amirfallah A, Kocal GC, Unal OU, Ellidokuz H, Oztop I, Basbinar Y. DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients. J Pers Med 2018;8:E45. [PMID: 30551678 DOI: 10.3390/jpm8040045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 2014;106:dju298. [PMID: 25381393 DOI: 10.1093/jnci/dju298] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 10.0] [Reference Citation Analysis]
101 Villalvazo P, Marzal-Alfaro B, García-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, García-González X, Calvo A, Yakoubi M, Salvador-Martín S, López-López F, Aguilar I, Sanjurjo-Sáez M, Martín M, López-Fernández LA. DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. J Pers Med 2021;11:792. [PMID: 34442436 DOI: 10.3390/jpm11080792] [Reference Citation Analysis]
102 Inati A, Akouri G, Abbas HA. A rare aggravation of severe mucositis post chemotherapy in a child with acute lymphoblastic leukemia. F1000Res 2013;2:196. [PMID: 24555093 DOI: 10.12688/f1000research.2-196.v1] [Reference Citation Analysis]
103 Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J. 2019;19:556-563. [PMID: 30723313 DOI: 10.1038/s41397-019-0077-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]